Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.
about
Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responsesSingle-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 virusesMicroneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in miceVaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionalityAdenoviral vectors as novel vaccines for influenza.Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Development of adenoviral vector-based mucosal vaccine against influenza.Novel viral vectored vaccines for the prevention of influenza.Novel vaccines to human rabiesImmunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infectionA preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer.Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging.Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathwayThe influence of delivery vectors on HIV vaccine efficacyAdenovirus-based vaccines: comparison of vectors from three species of adenoviridae.New approaches to design HIV-1 T-cell vaccinesThe effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses.A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challengeCD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination.Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c micePresence of adenovirus species C in infiltrating lymphocytes of human sarcomaHeterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruziEffect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vectorThe relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.Targeting of non-dominant antigens as a vaccine strategy to broaden T-cell responses during chronic viral infection.Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines.Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag.Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral loadCombined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccinesA Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria VaccineCD8+ T effector memory cells protect against liver-stage malaria.Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime.Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in miceIntranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs.Replicating and non-replicating viral vectors for vaccine developmentRelevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors.
P2860
Q27304910-2614EC15-63AF-442F-B8FD-EDEC79C0DCC1Q27318575-4104B0B2-61C2-4F4F-AACE-5FD8BE356702Q27331006-85E1E647-3AA7-4BE4-9E7A-1BB077BFA891Q28744027-C7D4A2F2-8A06-487E-9EC6-547F43C77977Q30370445-E230909E-D0BA-4FCC-A91E-7ABE310E8D9AQ30378897-C80E7450-798A-4267-8E6D-E3E6E262F698Q30396642-12CB50BE-EF21-45F6-BD1D-63E985B08F68Q30418570-B192BD3B-2096-41EB-AD7B-4F6612D889C1Q33507253-3D8ED531-8480-452D-B6D1-21E771BC4AF4Q33518452-8005490F-F1FB-40ED-BAC2-17D382672FFAQ33713730-7E843059-1FFB-4E45-A315-2AD57A7F8027Q33803963-CD5DA8F9-3F13-49AB-AAE2-527D5F472FDDQ33920141-2943FA62-E834-4FCA-A92D-6B6873C39F4EQ34077543-F873E883-3CA7-4C45-959F-8C9B1191DB2CQ34178208-1B58ADF3-456B-44CA-BFC2-BCABEA28A72FQ34274849-E792A417-0614-44E6-A7E9-EC62AE0CC669Q34341345-640BD442-A25C-4BC8-8DC9-31DAF3FD705BQ34383008-0FA18A40-3E92-4593-854B-70DF87FABE5BQ34447762-6C820204-73CB-4394-A2A4-A36E9121F689Q34592940-74006FF2-A1F9-439F-ABE0-E9B2F8015401Q34721197-1F727A03-CD40-4C6A-B22F-C59E43707C6FQ34931648-E51E906A-553A-4712-96B5-AD9BD6A71447Q35022798-A1B63D7F-BE40-4998-BCF1-7C255112EE51Q35091556-AE5939A3-5DF1-447F-BFC2-42105B07DB44Q35101608-DC528114-ED13-4F4E-A07E-061A84F72284Q35113347-D4AA7871-45CD-4C66-91FF-62CE4C3DC382Q35159523-C850777B-03B7-4DE6-A655-5B909C46635EQ35191980-9B3802C4-AB36-4E83-9ABF-348E49EBFC52Q35344875-0D73BFC9-218E-4CCE-8D44-3CD25DC2A503Q35621976-72F60BBB-3780-4F97-A79C-A11FAE21880DQ35876220-DB36FB3C-E651-410C-B9BB-86B5DE2CDF56Q36003208-556220AC-9EE8-441A-87CA-3034D355A2D3Q36055733-45703C2D-CF3F-463A-A9C3-4E77A276366CQ36144935-B8C44A37-D140-4E58-A72F-5B7071976CE8Q36166161-A18C2EDE-C15D-4C1D-8B43-EFA8322AB479Q36291682-A377BC60-090A-4A84-981E-D0F194B8DBFFQ36378581-4E2ACBE2-30A0-4EC4-B76E-B2D68FB6F450Q36464587-C4A32254-21AE-4BD3-A2B9-FCB73DDAE9C9Q36474557-23124731-90E5-439D-B5D7-429B802F592DQ36559772-3AB6D44F-8BFA-466A-8339-81B24789331F
P2860
Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Adenoviral vectors persist in ...... ons for their use as vaccines.
@ast
Adenoviral vectors persist in ...... ons for their use as vaccines.
@en
type
label
Adenoviral vectors persist in ...... ons for their use as vaccines.
@ast
Adenoviral vectors persist in ...... ons for their use as vaccines.
@en
prefLabel
Adenoviral vectors persist in ...... ons for their use as vaccines.
@ast
Adenoviral vectors persist in ...... ons for their use as vaccines.
@en
P2093
P2860
P50
P1433
P1476
Adenoviral vectors persist in ...... ions for their use as vaccines
@en
P2093
Amaya Iparraguirre
Dongming Zhou
E John Wherry
Hildegund C J Ertl
Kimberly C Harris-McCoy
Nia Tatsis
Scott E Hensley
Shih-Wen Lin
Zhi Quan Xiang
P2860
P304
P356
10.1182/BLOOD-2007-02-062117
P407
P577
2007-05-17T00:00:00Z